Sangamo Therapeutics (NASDAQ:SGMO) Now Covered by Analysts a

StockNews.com started coverage on shares of Sangamo Therapeutics (NASDAQ:SGMO – Free Report) in a report published on Wednesday. The brokerage issued a sell rating on the biopharmaceutical company’s stock. Several other research firms have also commented on SGMO. HC Wainwright reduced their price target on shares of Sangamo Therapeutics from $5.00 to $3.00 and set […]

Related Keywords

Canada , United States , , Wells Fargo Company , Biogen Inc , Sangamo Therapeutics Inc , Royal Bank , Acadian Asset Management , Sangamo Therapeutics Company Profile , Allspring Global Investments Holdings , Penserra Capital Management , Mirae Asset Global Investments Co , Securities Exchange Commission , Sangamo Therapeutics , Free Report , Get Free Report , Exchange Commission , Asset Global Investments , Global Investments Holdings , Capital Management , Asset Management , Sangamo Therapeutics Daily , Nasdaq Sgmo , Sgmo , Medical , 80067710 , Initiated Coverage , Stocknews Com ,